Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyDexbrompheniramine
Identification
- Name
- Dexbrompheniramine
- Accession Number
- DB00405 (APRD00770)
- Type
- Small Molecule
- Groups
- Approved
- Description
Dexbrompheniramine maleate is an antihistamine used to treat allergic conditions such as hay fever or urticaria.
- Structure
Structure for DB00405 (Dexbrompheniramine)
- Synonyms
- (+)-Brompheniraminum
- (+)-parabromdylamine
- (R)-3-(4-Bromophenyl)-3-(2-pyridyl)propyldimethylamine
- (S)-(+)-Brompheniramine
- (S)-Brompheniramine
- 3-(4-bromophenyl)- N,N-dimethyl- 3-pyridin-2-yl-propan-1-amine
- D-Brompheniramine
- Desbrofeniramina
- Dexbromfeniramina
- Dexbrompheniramin
- Dexbromphéniramine
- Dexbrompheniraminum
- Parabromodylamine
- Product Ingredients
Ingredient UNII CAS InChI Key Dexbrompheniramine maleate BPA9UT29BS 2391-03-9 SRGKFVAASLQVBO-DASCVMRKSA-N - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Ala-hist Ir Tablet 2 mg/1 Oral Poly Pharmaceuticals 2011-08-22 Not applicable US 
PediaVent Tablet, chewable 1 mg/1 Oral Carwin Associates, Inc 2014-08-05 Not applicable US PediaVent Syrup 2 mg/5mL Oral Carwin Associates, Inc 2014-08-04 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Acticon Dexbrompheniramine maleate (1 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL) Liquid Oral Actipharma, Inc 2016-07-14 Not applicable US Acticon Dexbrompheniramine maleate (2 mg/1) + Pseudoephedrine hydrochloride (60 mg/1) Tablet Oral Actipharma, Inc 2015-08-13 Not applicable US Actidogesic Dexbrompheniramine maleate (1 mg/1) + Acetaminophen (500 mg/1) Tablet Oral Actipharma, Inc 2016-10-14 Not applicable US Ala-hist PE Dexbrompheniramine maleate (2 mg/1) + Phenylephrine hydrochloride (10 mg/1) Tablet Oral Poly Pharmaceuticals 2011-09-15 Not applicable US Alahist CF Dexbrompheniramine maleate (2 g/1) + Dextromethorphan hydrobromide (20 g/1) + Phenylephrine hydrochloride (10 g/1) Tablet Oral Poly Pharmaceuticals 2017-09-14 Not applicable US Alahistdm DM Dexbrompheniramine maleate (2 mg/5mL) + Dextromethorphan hydrobromide (15 mg/5mL) + Phenylephrine hydrochloride (7.5 mg/5mL) Liquid Oral Poly Pharmaceuticals 2016-09-01 Not applicable US Bio-cnex Dexbrompheniramine maleate (1 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL) Liquid Oral Advanced Generic Corporation 2017-01-01 Not applicable US Biogesic Dexbrompheniramine maleate (1 mg/1) + Acetaminophen (500 mg/1) Tablet Oral Advanced Generic Corporation 2017-01-01 Not applicable US Bionatuss DXP Dexbrompheniramine maleate (2 mg/5mL) + Dextromethorphan hydrobromide (20 mg/5mL) + Phenylephrine hydrochloride (10 mg/5mL) Liquid Oral Advanced Generic Corporation 2009-10-01 Not applicable US Chlo Hist Dexbrompheniramine maleate (1 mg/5mL) + Chlophedianol hydrochloride (12.5 mg/5mL) Liquid Oral R. A. Mc Neil Company 2014-09-15 Not applicable US - International/Other Brands
- Disophrol (Schering) / Drixoral (Schering )
- Categories
- UNII
- 75T64B71RP
- CAS number
- 132-21-8
- Weight
- Average: 319.239
Monoisotopic: 318.073161265 - Chemical Formula
- C16H19BrN2
- InChI Key
- ZDIGNSYAACHWNL-HNNXBMFYSA-N
- InChI
- InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1
- IUPAC Name
- [(3S)-3-(4-bromophenyl)-3-(pyridin-2-yl)propyl]dimethylamine
- SMILES
- CN(C)CC[[email protected]@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1
Pharmacology
- Indication
For treatment and relief of symptoms of allergies, hay fever, and colds
- Structured Indications
- Pharmacodynamics
In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Dexbrompheniramine is a histamine H1 antagonist (or more correctly, an inverse histamine agonist) of the alkylamine class. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.
- Mechanism of action
Dexbrompheniramine competitively binds to the histamine H1-receptor. It competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.
Target Actions Organism AHistamine H1 receptor antagonistHuman - Absorption
Antihistamines are well absorbed from the gastrointestinal tract after oral administration.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Hepatic (cytochrome P-450 system), some renal.
- Route of elimination
- Not Available
- Half life
25 hours
- Clearance
- Not Available
- Toxicity
Signs of an overdose include fast or irregular heartbeat, mental or mood changes, tightness in the chest, and unusual tiredness or weakness.
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Dexbrompheniramine H1-Antihistamine Action Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Dexbrompheniramine. Experimental, Illicit 2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Dexbrompheniramine. Experimental 3,4-Methylenedioxyamphetamine 3,4-Methylenedioxyamphetamine may decrease the sedative activities of Dexbrompheniramine. Experimental, Illicit 4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Dexbrompheniramine. Experimental, Illicit 7-Nitroindazole The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with 7-Nitroindazole. Experimental Acepromazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Aceprometazine. Approved Adipiplon The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Adipiplon. Investigational Agomelatine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Agomelatine. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alaproclate. Experimental Alfaxalone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Dexbrompheniramine. Approved, Illicit Allopregnanolone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Allopregnanolone. Investigational Alphacetylmethadol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alphacetylmethadol. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Dexbrompheniramine. Approved, Illicit, Investigational Amisulpride The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Amisulpride. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Dexbrompheniramine. Approved Amobarbital The risk or severity of adverse effects can be increased when Amobarbital is combined with Dexbrompheniramine. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Amoxapine. Approved Amperozide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Amperozide. Experimental Amphetamine Amphetamine may decrease the sedative activities of Dexbrompheniramine. Approved, Illicit, Investigational Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Dexbrompheniramine. Approved, Investigational Articaine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Articaine. Approved Asenapine The risk or severity of adverse effects can be increased when Asenapine is combined with Dexbrompheniramine. Approved Azaperone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Azaperone. Investigational, Vet Approved Azelastine Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Dexbrompheniramine. Approved Barbital The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Barbital. Illicit Benperidol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Benperidol. Approved, Investigational Benzocaine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Benzocaine. Approved, Investigational Benzphetamine Benzphetamine may decrease the sedative activities of Dexbrompheniramine. Approved, Illicit Benzyl alcohol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Benzyl alcohol. Approved Benzylpenicilloyl Polylysine Dexbrompheniramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent. Approved Betahistine The therapeutic efficacy of Betahistine can be decreased when used in combination with Dexbrompheniramine. Approved, Investigational Brexpiprazole The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brexpiprazole. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. Approved Bromazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Dexbrompheniramine. Approved, Illicit, Investigational Bromisoval The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Bromisoval. Experimental Bromperidol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Bromperidol. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brompheniramine. Approved Brotizolam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brotizolam. Approved, Investigational, Withdrawn Bupivacaine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Bupivacaine. Approved, Investigational Buprenorphine Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Buspirone The risk or severity of adverse effects can be increased when Buspirone is combined with Dexbrompheniramine. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Dexbrompheniramine. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Butalbital is combined with Dexbrompheniramine. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Butamben. Approved, Withdrawn Butethal The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Butethal. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Dexbrompheniramine. Approved, Illicit, Vet Approved Canertinib The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Canertinib. Investigational Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Dexbrompheniramine. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Carbinoxamine. Approved Carfentanil The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Carfentanil. Illicit, Investigational, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Dexbrompheniramine. Approved Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Dexbrompheniramine. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chloral hydrate. Approved, Illicit, Investigational, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dexbrompheniramine. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chlormezanone. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chloroprocaine. Approved Chlorphenamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chlorphenamine. Approved Chlorphentermine Chlorphentermine may decrease the sedative activities of Dexbrompheniramine. Illicit, Withdrawn Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dexbrompheniramine. Approved, Investigational, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chlorprothixene. Approved, Investigational, Withdrawn Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dexbrompheniramine. Approved Cinchocaine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cinchocaine. Approved, Vet Approved Citalopram The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Citalopram. Approved Clemastine The risk or severity of adverse effects can be increased when Clemastine is combined with Dexbrompheniramine. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clidinium. Approved Clobazam The risk or severity of adverse effects can be increased when Clobazam is combined with Dexbrompheniramine. Approved, Illicit clomethiazole The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with clomethiazole. Investigational Clomipramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clomipramine. Approved, Investigational, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clonazepam. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clonidine. Approved Clopenthixol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clopenthixol. Experimental Clorazepate The risk or severity of adverse effects can be increased when Clorazepate is combined with Dexbrompheniramine. Approved, Illicit Clothiapine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clothiapine. Experimental Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Dexbrompheniramine. Approved Cocaine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cocaine. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Dexbrompheniramine. Approved, Illicit Cyclizine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyclizine. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dexbrompheniramine. Approved Cyclopropane The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyclopropane. Experimental Cyproheptadine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyproheptadine. Approved Dantrolene The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dantrolene. Approved, Investigational Dapiprazole The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dapiprazole. Approved Dapoxetine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dapoxetine. Investigational Deramciclane The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Dexbrompheniramine. Approved Desipramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desipramine. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desloratadine. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desvenlafaxine. Approved, Investigational Detomidine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Detomidine. Vet Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dexmedetomidine. Approved, Vet Approved Dextroamphetamine Dextroamphetamine may decrease the sedative activities of Dexbrompheniramine. Approved, Illicit Dextromoramide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dextropropoxyphene. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dezocine. Approved, Investigational Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Dexbrompheniramine. Approved, Illicit, Investigational, Vet Approved Diethyl ether The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Diethyl ether. Experimental Diethylpropion Diethylpropion may decrease the sedative activities of Dexbrompheniramine. Approved, Illicit Difenoxin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Difenoxin. Approved, Illicit Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dexbrompheniramine. Approved, Illicit Dihydroetorphine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dihydroetorphine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dihydromorphine. Experimental, Illicit Dimenhydrinate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dimenhydrinate. Approved Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dexbrompheniramine. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dexbrompheniramine. Approved, Illicit Dixyrazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dixyrazine. Experimental Doramectin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Doramectin. Vet Approved Doxepin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Doxepin. Approved, Investigational Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. Approved, Illicit Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Drotebanol. Experimental, Illicit Duloxetine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dyclonine. Approved Ecgonine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ecgonine. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ecopipam. Investigational Efavirenz The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Efavirenz. Approved, Investigational Eltanolone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Eltanolone. Investigational Enflurane The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Enflurane. Approved, Investigational, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Entacapone. Approved, Investigational Escitalopram The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Escitalopram. Approved, Investigational Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Dexbrompheniramine. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Eszopiclone is combined with Dexbrompheniramine. Approved, Investigational Ethanol Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethchlorvynol. Approved, Illicit, Withdrawn Ethosuximide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethosuximide. Approved Ethotoin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethotoin. Approved Ethyl carbamate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethyl loflazepate. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethylmorphine. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etifoxine. Investigational, Withdrawn Etizolam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etomidate. Approved Etoperidone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etoperidone. Withdrawn Etorphine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etorphine. Illicit, Vet Approved Ezogabine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ezogabine. Approved, Investigational Felbamate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Felbamate. Approved Fencamfamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fencamfamine. Approved, Illicit, Withdrawn Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Dexbrompheniramine. Approved, Illicit, Investigational, Vet Approved Fexofenadine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fexofenadine. Approved, Investigational Flibanserin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Flibanserin. Approved, Investigational Fluanisone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluanisone. Experimental Fludiazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fludiazepam. Approved, Illicit Flunarizine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Flunarizine. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Flunitrazepam. Approved, Illicit Fluoxetine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of adverse effects can be increased when Flupentixol is combined with Dexbrompheniramine. Approved, Investigational, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Dexbrompheniramine. Approved Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Dexbrompheniramine. Approved, Illicit, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluticasone propionate. Approved Fluvoxamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluvoxamine. Approved, Investigational Fosphenytoin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fosphenytoin. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fospropofol. Approved, Illicit, Investigational Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Dexbrompheniramine. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gabapentin Enacarbil. Approved, Investigational Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dexbrompheniramine. Approved, Illicit, Investigational Gepefrine Gepefrine may decrease the sedative activities of Dexbrompheniramine. Experimental Gepirone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gepirone. Investigational Glutethimide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Glutethimide. Approved, Illicit Guanfacine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Guanfacine. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Halazepam. Approved, Illicit, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Haloperidol is combined with Dexbrompheniramine. Approved Halothane The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Halothane. Approved, Vet Approved Heroin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Heroin. Approved, Illicit, Investigational Hexobarbital The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Hexobarbital. Approved Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexbrompheniramine. Approved, Investigational Hydrocodone Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dexbrompheniramine. Approved, Illicit Hydroxyamphetamine Hydroxyamphetamine may decrease the sedative activities of Dexbrompheniramine. Approved Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. Approved Iloperidone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Iloperidone. Approved Imipramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Imipramine. Approved Indalpine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Indalpine. Investigational, Withdrawn Indiplon The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Indiplon. Investigational Iofetamine I-123 Iofetamine I-123 may decrease the sedative activities of Dexbrompheniramine. Approved Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Dexbrompheniramine. Approved, Vet Approved Ketamine The risk or severity of adverse effects can be increased when Ketamine is combined with Dexbrompheniramine. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ketazolam. Approved Ketobemidone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ketobemidone. Approved, Investigational Lamotrigine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lamotrigine. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levetiracetam. Approved, Investigational Levobupivacaine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levobupivacaine. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levocabastine. Approved, Investigational Levocetirizine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levocetirizine. Approved Levodopa The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levodopa. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levomethadyl Acetate. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levomilnacipran. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Dexbrompheniramine. Approved Lidocaine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lidocaine. Approved, Vet Approved Lisdexamfetamine Lisdexamfetamine may decrease the sedative activities of Dexbrompheniramine. Approved, Investigational Lithium The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lithium. Approved Lofentanil The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lofentanil. Illicit Lofexidine The therapeutic efficacy of Dexbrompheniramine can be increased when used in combination with Lofexidine. Approved, Investigational Loprazolam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Loprazolam. Experimental Loratadine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Loratadine. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Dexbrompheniramine. Approved Lormetazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lormetazepam. Approved Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Dexbrompheniramine. Approved Lurasidone The risk or severity of adverse effects can be increased when Lurasidone is combined with Dexbrompheniramine. Approved, Investigational Magnesium sulfate The therapeutic efficacy of Dexbrompheniramine can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Maprotiline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Maprotiline. Approved, Investigational Mebicar The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mebicar. Experimental Meclizine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Meclizine. Approved Medazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Medetomidine. Vet Approved Melatonin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Melatonin. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Melperone. Approved, Investigational Mephedrone Mephedrone may decrease the sedative activities of Dexbrompheniramine. Investigational Mephentermine Mephentermine may decrease the sedative activities of Dexbrompheniramine. Approved Mepivacaine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mepivacaine. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Dexbrompheniramine. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Meptazinol. Experimental Mesoridazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mesoridazine. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Metaxalone. Approved Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Dexbrompheniramine. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methadyl Acetate. Approved, Illicit Methamphetamine Methamphetamine may decrease the sedative activities of Dexbrompheniramine. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methaqualone. Illicit, Withdrawn Methocarbamol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methocarbamol. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Methohexital is combined with Dexbrompheniramine. Approved Methotrimeprazine Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxyflurane The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methoxyflurane. Approved, Investigational, Vet Approved Methoxyphenamine Methoxyphenamine may decrease the sedative activities of Dexbrompheniramine. Experimental Methsuximide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methsuximide. Approved Methylecgonine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methylecgonine. Experimental Methylphenobarbital The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methylphenobarbital. Approved Metyrosine Dexbrompheniramine may increase the sedative activities of Metyrosine. Approved Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Dexbrompheniramine. Approved, Illicit Midomafetamine Midomafetamine may decrease the sedative activities of Dexbrompheniramine. Experimental, Illicit, Investigational Milnacipran The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Milnacipran. Approved, Investigational Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. Approved, Investigational Mirtazapine Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved MMDA MMDA may decrease the sedative activities of Dexbrompheniramine. Experimental, Illicit Molindone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Molindone. Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Dexbrompheniramine. Approved, Investigational Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. Approved, Investigational Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Dexbrompheniramine. Approved Nefazodone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nefazodone. Approved, Withdrawn Nitrazepam The risk or severity of adverse effects can be increased when Nitrazepam is combined with Dexbrompheniramine. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Dexbrompheniramine. Approved, Vet Approved Norflurane The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Norflurane. Approved, Investigational Normethadone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nortriptyline. Approved Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Dexbrompheniramine. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Olopatadine. Approved Ondansetron The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ondansetron. Approved Opium The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Opium. Approved, Illicit Orphenadrine Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Osanetant. Investigational Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Dexbrompheniramine. Approved Oxetacaine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxetacaine. Approved, Investigational Oxprenolol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxprenolol. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxybuprocaine. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Dexbrompheniramine. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Dexbrompheniramine. Approved, Investigational, Vet Approved Paliperidone The risk or severity of adverse effects can be increased when Paliperidone is combined with Dexbrompheniramine. Approved Paraldehyde Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Paroxetine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Paroxetine. Approved, Investigational Penfluridol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Penfluridol. Experimental Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Dexbrompheniramine. Approved, Vet Approved Pentobarbital The risk or severity of adverse effects can be increased when Pentobarbital is combined with Dexbrompheniramine. Approved, Investigational, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. Approved Perazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Perazine. Approved, Investigational Perospirone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Dexbrompheniramine. Approved Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Dexbrompheniramine. Approved Phenazocine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phenazocine. Experimental Phenibut The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phenibut. Experimental Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with Dexbrompheniramine. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phenoperidine. Experimental Phenoxyethanol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phenoxyethanol. Approved Phentermine Phentermine may decrease the sedative activities of Dexbrompheniramine. Approved, Illicit Phenytoin The risk or severity of adverse effects can be increased when Phenytoin is combined with Dexbrompheniramine. Approved, Vet Approved Pimozide The risk or severity of adverse effects can be increased when Pimozide is combined with Dexbrompheniramine. Approved Pipamperone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pipamperone. Approved, Investigational Pipotiazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pipotiazine. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Piritramide. Approved, Investigational Pizotifen The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pizotifen. Approved Pomalidomide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pomalidomide. Approved Pramipexole Dexbrompheniramine may increase the sedative activities of Pramipexole. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pramocaine. Approved Prazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Prazepam. Approved, Illicit Pregabalin The therapeutic efficacy of Dexbrompheniramine can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Prilocaine. Approved Primidone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Primidone. Approved, Vet Approved Procaine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Procaine. Approved, Investigational, Vet Approved Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dexbrompheniramine. Approved, Vet Approved Promazine The risk or severity of adverse effects can be increased when Promazine is combined with Dexbrompheniramine. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Promethazine. Approved, Investigational Propanidid The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Propanidid. Experimental Proparacaine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Proparacaine. Approved, Vet Approved Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Dexbrompheniramine. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Propoxycaine. Approved Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Dexbrompheniramine. Approved Proxibarbal The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Proxibarbal. Experimental PSD502 The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with PSD502. Investigational Pseudoephedrine Pseudoephedrine may decrease the sedative activities of Dexbrompheniramine. Approved Quazepam The risk or severity of adverse effects can be increased when Quazepam is combined with Dexbrompheniramine. Approved, Illicit Quetiapine The risk or severity of adverse effects can be increased when Quetiapine is combined with Dexbrompheniramine. Approved Quinisocaine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Quinisocaine. Experimental Raclopride The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ramelteon. Approved, Investigational Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Dexbrompheniramine. Approved Remoxipride The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Remoxipride. Approved, Withdrawn Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Dexbrompheniramine. Approved, Investigational Risperidone The risk or severity of adverse effects can be increased when Risperidone is combined with Dexbrompheniramine. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ritanserin. Investigational Ritobegron Ritobegron may decrease the sedative activities of Dexbrompheniramine. Investigational Romifidine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Romifidine. Vet Approved Ropinirole Dexbrompheniramine may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ropivacaine. Approved Rotigotine Dexbrompheniramine may increase the sedative activities of Rotigotine. Approved Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Dexbrompheniramine. Approved Scopolamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Scopolamine. Approved, Investigational Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Dexbrompheniramine. Approved, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sepranolone. Investigational Sertindole The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sertindole. Approved, Investigational, Withdrawn Sertraline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Dexbrompheniramine. Approved, Vet Approved Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. Approved Stiripentol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Stiripentol. Approved Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Dexbrompheniramine. Approved, Investigational Sulpiride The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sulpiride. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sultopride. Experimental Suvorexant Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. Approved Tasimelteon The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tasimelteon. Approved, Investigational Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Dexbrompheniramine. Approved, Investigational Tetrabenazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tetrabenazine. Approved, Investigational Tetracaine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tetracaine. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tetrodotoxin. Investigational Thalidomide Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Thiamylal The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Thiamylal. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Thiopental. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Thioridazine is combined with Dexbrompheniramine. Approved, Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Thiothixene is combined with Dexbrompheniramine. Approved Tiagabine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tiagabine. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tiapride. Approved, Investigational Tiletamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tilidine. Experimental Tizanidine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tizanidine. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Dexbrompheniramine. Approved, Withdrawn Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Dexbrompheniramine. Approved Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Dexbrompheniramine. Approved, Investigational Tranylcypromine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tranylcypromine. Approved, Investigational Trazodone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trazodone. Approved, Investigational Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Dexbrompheniramine. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tricaine methanesulfonate. Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trichloroethylene. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dexbrompheniramine. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Triflupromazine. Approved, Vet Approved Trimipramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trimipramine. Approved Triprolidine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Triprolidine. Approved Valproic Acid The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Valproic Acid. Approved, Investigational Venlafaxine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Veralipride. Experimental Vigabatrin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vigabatrin. Approved Vinyl ether The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vinyl ether. Experimental Vortioxetine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vortioxetine. Approved, Investigational Xenon The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Xenon. Experimental Xylazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Xylazine. Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Dexbrompheniramine. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ziconotide. Approved Zimelidine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zimelidine. Withdrawn Ziprasidone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dexbrompheniramine. Approved Zolazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zolazepam. Vet Approved Zolpidem Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zonisamide. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Zopiclone is combined with Dexbrompheniramine. Approved Zotepine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zotepine. Approved, Investigational, Withdrawn Zuclopenthixol The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dexbrompheniramine. Approved, Investigational - Food Interactions
- Not Available
References
- Synthesis Reference
Walter, L.A.; U.S. Patents 3,061,517; October 30, 1962; and 3,030,371; April 17, 1962; both assigned to Schering Corporation.
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0014549
- PubChem Compound
- 16960
- PubChem Substance
- 46505186
- ChemSpider
- 16068
- ChEBI
- 59269
- ChEMBL
- CHEMBL1201287
- Therapeutic Targets Database
- DAP001068
- PharmGKB
- PA164746251
- Wikipedia
- Dexbrompheniramine
- ATC Codes
- R06AB56 — Dexbrompheniramine, combinations
- R06AB — Substituted alkylamines
- R06A — ANTIHISTAMINES FOR SYSTEMIC USE
- R06 — ANTIHISTAMINES FOR SYSTEMIC USE
- R — RESPIRATORY SYSTEM
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Schering corp sub schering plough corp
- Packagers
- Poly Pharmaceuticals Inc.
- Dosage forms
Form Route Strength Tablet Oral 2 mg/1 Tablet Oral Tablet, extended release Oral Tablet; tablet, extended release Oral Liquid Oral Syrup Oral 2 mg/5mL Tablet, chewable Oral 1 mg/1 Syrup Oral - Prices
Unit description Cost Unit Ala-hist ir 2 mg tablet 0.82USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 113-115 US. Patent 3,030,371. logP 3.4 Not Available - Predicted Properties
Property Value Source Water Solubility 0.0127 mg/mL ALOGPS logP 3.63 ALOGPS logP 3.75 ChemAxon logS -4.4 ALOGPS pKa (Strongest Basic) 9.48 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 16.13 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 83.67 m3·mol-1 ChemAxon Polarizability 31.84 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9648 Blood Brain Barrier + 0.9576 Caco-2 permeable + 0.8867 P-glycoprotein substrate Substrate 0.6242 P-glycoprotein inhibitor I Non-inhibitor 0.8782 P-glycoprotein inhibitor II Non-inhibitor 0.93 Renal organic cation transporter Inhibitor 0.7955 CYP450 2C9 substrate Non-substrate 0.8345 CYP450 2D6 substrate Substrate 0.8346 CYP450 3A4 substrate Substrate 0.5898 CYP450 1A2 substrate Non-inhibitor 0.9045 CYP450 2C9 inhibitor Non-inhibitor 0.9071 CYP450 2D6 inhibitor Inhibitor 0.8932 CYP450 2C19 inhibitor Non-inhibitor 0.9025 CYP450 3A4 inhibitor Non-inhibitor 0.8398 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7748 Ames test Non AMES toxic 0.9351 Carcinogenicity Non-carcinogens 0.9349 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 3.0758 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9121 hERG inhibition (predictor II) Inhibitor 0.7207
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-0292-0940000000-f369442eba5344b3ecb4
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as pheniramines. These are compounds containing a pheniramine moiety, which is structurally characterized by the presence of a 2-benzylpyridine linked to an dimethyl(propyl)amine to form a dimethyl[3-phenyl-3-(pyridin-2-yl)propyl]amine skeleton.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Pyridines and derivatives
- Sub Class
- Pheniramines
- Direct Parent
- Pheniramines
- Alternative Parents
- Bromobenzenes / Aralkylamines / Aryl bromides / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organobromides / Hydrocarbon derivatives
- Substituents
- Pheniramine / Bromobenzene / Halobenzene / Aralkylamine / Aryl bromide / Benzenoid / Monocyclic benzene moiety / Aryl halide / Heteroaromatic compound / Tertiary aliphatic amine
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- brompheniramine (CHEBI:59269)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Histamine receptor activity
- Specific Function
- In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
- Gene Name
- HRH1
- Uniprot ID
- P35367
- Uniprot Name
- Histamine H1 receptor
- Molecular Weight
- 55783.61 Da
References
- McLeod RL, Mingo G, O'Reilly S, Ruck LA, Bolser DC, Hey JA: Antitussive action of antihistamines is independent of sedative and ventilation activity in the guinea pig. Pharmacology. 1998 Aug;57(2):57-64. [PubMed:9691225]
- Bokesoy TA, Onaran HO: Atypical Schild plots with histamine H1 receptor agonists and antagonists in the rabbit aorta. Eur J Pharmacol. 1991 May 2;197(1):49-56. [PubMed:1680053]
- Onaran HO, Bokesoy TA: Kinetics of antagonism at histamine-H1 receptors in isolated rabbit arteries. Naunyn Schmiedebergs Arch Pharmacol. 1990 Apr;341(4):316-23. [PubMed:1970615]
- Yanni JM, Stephens DJ, Parnell DW, Spellman JM: Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use. J Ocul Pharmacol. 1994 Winter;10(4):665-75. [PubMed:7714410]
- Sadofsky LR, Campi B, Trevisani M, Compton SJ, Morice AH: Transient receptor potential vanilloid-1-mediated calcium responses are inhibited by the alkylamine antihistamines dexbrompheniramine and chlorpheniramine. Exp Lung Res. 2008 Dec;34(10):681-93. doi: 10.1080/01902140802339623. [PubMed:19085565]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Drug created on June 13, 2005 07:24 / Updated on May 02, 2018 01:28